Medi-Tate

Company Overview

Snapshot

Founded in February 2007 by Ido Kilemnik, Medi-Tate operates with 1-10 employees. The company secured funding across three rounds from three investors, including Xenia Venture Capital. Medi-Tate was acquired by Olympus Corporation in February 2021.

Business overview

Medi-Tate develops innovative solutions for treating diseases of the urethra and prostate, aiming to alleviate symptoms and enhance patients' quality of life. Its core product, the iTind system, is a minimally invasive device designed to treat benign prostate hyperplasia (BPH). The device reshapes the prostate by pushing obstructive tissue aside, providing a long-term therapeutic effect. It can be deployed in various clinical settings using standard rigid cystoscopy equipment, allowing patients to return to normal activities immediately post-procedure. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving patients and healthcare providers in markets such as Europe, Canada, Hong Kong, and Israel.

Strategic signal

In June 2022, Medi-Tate's iTind device for BPH treatment saw its first procedures performed in Canada. This expansion into the Canadian market signals continued post-acquisition growth and broader market adoption for the company's minimally invasive solution, indicating strong commercial momentum and strategic validation for investors.

Company Intelligence Q&A

What was a key regulatory achievement for Medi-Tate?

In March 2020, Medi-Tate's iTind system for benign prostatic hyperplasia received FDA De Novo classification, green-lighting its use in the US market.

What recent market expansion did Medi-Tate achieve?

In June 2022, the first BPH treatment procedures using Medi-Tate's iTind device were performed in Canada, marking a new geographical market for the company.